PBI-Gordon Companies, Inc., the parent company of TriviumVet, which holds sole conditional new animal drug approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) under its affiliated brand company Pegasus, issued a cease-and-desist demand letter to Petspan for falsely promoting a compounded version of rapamycin (synonymous with sirolimus) for the treatment … [Read more...]
PBI-Gordon Companies acquires TriviumVet
The acquisition of TriviumVet brings the addition of an innovative new product, Felycin®-CA1, to the PRN® Pharmacal portfolio of products. Felycin is the only FDA conditionally approved drug for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), one of the most common and life-threatening diseases in cats. TriviumVet adds … [Read more...]